Full-Time

Quality Assurance Specialist III

External Manufacturing

Confirmed live in the last 24 hours

Vaxcyte

Vaxcyte

201-500 employees

Develops vaccines for bacterial infections

Biotechnology
Healthcare

Compensation Overview

$123k - $134kAnnually

+ Equity Component + Comprehensive Benefits

Senior

Remote in USA

Open to remote.

Category
QA & Testing
Quality Assurance
Requirements
  • Bachelor’s degree in Chemistry, Biology, Pharmacy, Engineering, or a related field.
  • Minimum of 5+ years of experience in quality assurance, batch record review, manufacture, or quality systems management within the pharmaceutical, biotechnology, or life sciences industry.
  • Strong knowledge of cGMP, ICH guidelines, FDA/EMA regulations, and other international pharmaceutical quality standards.
  • Demonstrated experience managing batch record review and deviation resolution.
  • Great organization skills and have an attention to detail.
  • In-depth understanding of biologics manufacturing operations.
  • Good ability to prioritize multiple assignments and changing priorities.
  • Excellent problem-solving skills and the ability to manage complex investigations and root cause analyses.
  • Strong written and verbal communication skills, with the ability to clearly present quality issues to cross-functional teams.
Responsibilities
  • GxP Batch Record and Product or Program Document Review for API, Intermediate, and/or Drug Substance product: Reviewing executed batch records, product or program specific documents, deviation and change control review and approval, documenting batch review comments, and effectively working with cross functional team, may be the primary QA point of contact with CDMO.
  • Product Disposition: Performing activities associated with disposition of product (e.g. document review and approval, document archival, raw data review).
  • Problem Solving: Representing Quality Assurance in support of Deviations, Change Controls, CAPAs, etc., including active participation in investigation, evaluation, and problem resolution. Effective, independent conflict resolution.
  • Technology Transfer and Validation: May participate as a QA representative on Technology Transfer and/or Validation Teams where responsibilities include providing guidance on QA procedures and policies as well as review of documents for both internal and external transfers.
  • Documentation and Reporting: Reviewing, editing, or approving controlled documents. Maintain accurate and thorough documentation of related quality activities.
  • Regulatory Compliance: Ensure all disposition-related activities comply with global regulatory requirements, including FDA, EMA, ICH guidelines, and other applicable regulations.
  • Cross-functional Collaboration: Work closely with global manufacturing, and external vendors to address quality issues and support product development and commercialization.
  • Continuous Improvement: Drive improvements in batch record review processes and procedures by identifying gaps, recommending solutions, and implementing best practices.

Vaxcyte develops vaccines aimed at preventing bacterial infections, focusing on diseases like invasive pneumococcal disease, Group A Strep, periodontitis, and Shigella. Their lead product, VAX-24, is a pneumococcal conjugate vaccine that targets 24 strains of the Streptococcus pneumoniae bacteria and has received Breakthrough Therapy designation from the FDA. Vaxcyte utilizes advanced chemistry and a proprietary cell-free protein synthesis platform, XpressCF™, to create vaccines that can effectively address the complex defenses of bacteria while stimulating an immune response. This method sets them apart from traditional cell-based vaccine production. The company's goal is to develop and commercialize broad-spectrum vaccines to improve global health outcomes, particularly for vulnerable populations.

Company Stage

IPO

Total Funding

$273.3M

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

24%

1 year growth

63%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • Vaxcyte's VAX-24 has FDA Breakthrough Therapy designation for pneumococcal disease prevention.
  • The global pneumococcal vaccine market is projected to grow at a 5.6% CAGR until 2030.
  • Recent $1.5 billion public offering strengthens Vaxcyte's financial position for future developments.

What critics are saying

  • Competition from mRNA vaccine developers could threaten Vaxcyte's market share.
  • Reliance on XpressCF™ platform may limit adaptability to new scientific advancements.
  • Potential delays in clinical trials could impact Vaxcyte's financial performance and market position.

What makes Vaxcyte unique

  • Vaxcyte uses the XpressCF™ platform for cell-free protein synthesis in vaccine development.
  • Their lead product, VAX-24, targets 24 strains of Streptococcus pneumoniae.
  • Vaxcyte focuses on broad-spectrum vaccines for bacterial infections like pneumococcal disease and Group A Strep.

Help us improve and share your feedback! Did you find this helpful?